Myelosuppression After Frontline Fludarabine, Cyclophosphamide, and Rituximab in Patients With Chronic Lymphocytic Leukemia: Analysis of Persistent and New-Onset Cytopenia

BACKGROUND: The combination of fludarabine, cyclophosphamide, and rituximab (FCR) has produced improved response rates and a prolonged survival in patients with chronic lymphocytic leukemia (CLL). However, its therapeutic power is counterbalanced by significant hematologic toxicity. Persistent and n...

Full description

Saved in:
Bibliographic Details
Published in:Cancer
Main Authors: Strati, Paolo, Wierda, William, Burger, Jan, Ferrajoli, Alessandra, Tam, Constantine, Lerner, Susan, Keating, Michael J., O’Brien, Susan
Format: Artigo
Language:Inglês
Published: 2013
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4535913/
https://ncbi.nlm.nih.gov/pubmed/23943357
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.28318
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items